• News
  • SAN DIEGO
  • BioTech

FDA gives Isis green light for cholesterol drug

The U.S. Food and Drug Administration has approved a new cholesterol treatment from Carlsbad’s Isis Pharmaceuticals (Nasdaq: ISIS) and its French partner Genzyme, clearing the path for Isis' first drug to reach market.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
65.16
  -0.17  
- 0.26%
1,453,459,000
77.80
22.25

Insider Trade Data

Date Insider Shares Type Value
04/17/2015 Berthelsen, Spencer R 10,000 Exchange $39,500
04/01/2015 Crooke, Stanley T 21,623 Sell $1,339,158
04/01/2015 Crooke, Stanley T 21,623 Exchange $239,661
04/01/2015 Parshall, B Lynne 5,377 Sell $333,009
04/01/2015 Parshall, B Lynne 5,377 Exchange $78,988

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!